New therapeutic targets for osteoporosis

Area of Science:

• Endocrinology and Bone Metabolism
• Pharmacology of Osteoporosis Therapeutics
• Clinical Osteology

Background:

• Osteoporosis treatment has advanced with new anabolic agents.
• Current anabolic therapies include parathyroid hormone (PTH) and PTH-related peptide (PTHrP) analogues: teriparatide and abaloparatide.
• Romosozumab, a sclerostin inhibitor, also shows anabolic and anti-resorptive effects.

Purpose of the Study:

• To review current and emerging anti-osteoporotic agents.
• To compare the efficacy and safety profiles of different osteoporosis therapies.
• To discuss optimal sequencing of anabolic and anti-resorptive treatments.

Main Methods:

• Review of clinical trial data and pharmacological studies on osteoporosis medications.
• Comparative analysis of bone mineral density (BMD) gains and fracture risk reduction.
• Evaluation of safety data, including adverse events like hypercalcemia and cardiovascular risk.

Main Results:

• Teriparatide and abaloparatide increase bone formation and reduce fracture risk, with abaloparatide showing greater BMD gain and efficacy for major osteoporotic fractures.
• Romosozumab effectively reduces vertebral, non-vertebral, and hip fractures but carries cardiovascular risk concerns.
• Sequential therapy with an anabolic agent followed by an anti-resorptive (e.g., denosumab) maximizes BMD benefits.

Conclusions:

• New anabolic agents offer improved therapeutic options for osteoporosis.
• Careful consideration of efficacy, safety, and patient risk factors is crucial for treatment selection.
• Further longitudinal data are needed to fully establish the long-term efficacy and safety of these interventions.